secwatch.observer — SEC 8-K summary
======================================

Issuer:     COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK:        0001267565
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001558370-25-010647
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Collegium Q2 revenue $188M (+29% YoY); raises 2025 guidance; authorizes $150M buyback
--------------------------------------------------------------------------------

- Record quarterly product revenue $188.0M, up 29% YoY; GAAP EPS $0.34 diluted; adjusted EPS $1.68.
- Jornay PM net revenue $32.6M, prescriptions up 23% YoY; full-year Jornay PM guidance raised to $140-145M.
- Pain portfolio revenue $155.4M (+7% YoY) with Belbuca $52.6M, Xtampza $52.6M, Nucynta $46.4M.
- Raised FY2025 revenue guidance to $745-760M and adjusted EBITDA to $440-455M; cash $222.2M.
- Board authorized $150M share repurchase through Dec 2026; completed $25M ASR in July.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1267565/000155837025010647/0001558370-25-010647-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1267565/000155837025010647/coll-20250807x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-010647

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer